What about the acquisition of a marketing and distribution company?
In an interview following the third Phase 2 result, the topic of acquisition was raised by the interviewer. I think it’s in the context of additions to the drug pipeline, but why not bolt on a sales and marketing division and retain all the value of NNZ-2591?
Timestamp: 23:30
On the Couch with Jon Pilcher: What’s Next for Neuren Pharma
A search on Grok suggests there are a few options that could be "affordable" (less than $1B). With successful Phase 3 approvals, we should be worth US$7–10B, so it could be a good investment.
Ann: Update - Notification of buy-back - NEU, page-50
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
-0.140(1.07%) |
Mkt cap ! $1.612B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.82 | $4.627M | 354.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7585 | $12.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.03 | 3344 | 2 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |